|
|
Article: FDA Clears VaxGen's IND for an Attenuated Smallpox Vaccine Candidate.
- Article from:
- PR Newswire
- Article date:
- September 7, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VaxGen, Inc. (Pink Sheets: VXGN.PK) announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the company's candidate smallpox vaccine, LC16m8.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
The effective IND will allow VaxGen to begin clinical development of LC16m8 with the objective of meeting the U.S. government's stated interest in acquiring an emergency stockpile of an attenuated smallpox vaccine(1) and licensing the product for commercial sales. The U.S. government has indicated that it anticipates spending $1.9 billion to establish and maintain a stockpile of ...